Generic Name and Formulations:
Brinzolamide 1%; oph. susp; contains benzalkonium chloride.
Alcon Laboratories, Inc.
Indications for AZOPT:
Open-angle glaucoma. Ocular hypertension.
1 drop 3 times daily.
Hepatic impairment. Severe renal impairment (CrCl <30mL/min): not recommended. Discontinue if serious systemic, ocular (eg, conjunctivitis, lid edema), or hypersensitivity reactions occur. Soft contact lenses (remove; may reinsert 15 minutes after administration). Pregnancy (Cat.C). Nursing mothers: not recommended.
Carbonic anhydrase inhibitor (sulfonamide).
Concomitant oral carbonic anhydrase inhibitors: not recommended. Separate administration of other oph drugs by ≥10 minutes.
Blurred vision, bitter/sour taste, blepharitis, dermatitis, dry eye, foreign body sensation, headache, hyperemia; ocular discharge, discomfort, or itch; keratitis, rhinitis.
Susp—2.5mL, 5mL, 10mL, 15mL
Neurology Advisor Articles
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Patients With Multiple Sclerosis Face Greater Infection Risk
- Fingolimod Compared With Glatiramer Acetate in Head-to-Head MS Study
- Lower Relapse Risk and Disability Progression With Oral DMT in Treatment-Naive RRMS
- Anodal tDCS Offers Possible Benefit for Improving Item Recall in Post-Stroke Aphasia
- Hospitalization Tied to Brain Abnormalities in Older Adults
- Spending Often Persists in High-Cost Medicare-Medicaid Eligible
- Skills-Based Intervention Did Not Cut Systolic BP After Stroke, TIA
- High Frequency of Headaches Following Dialysis Associated With BUN and Blood Pressure